Shionogi advances Torii acquisition after regulatory clearance

Shionogi & Co. (TSE:4507) is proceeding with its tender offer to acquire TORII Pharmaceutical Co., Ltd. (TSE:4551) following the receipt of a "Notice of Non-issuance of Cease and Desist Order" from the Japan Fair Trade Commission (JFTC) on May 28, 2025. This regulatory clearance addresses previous uncertainties related to antitrust concerns. The tender offer, initially announced on May 7, 2025, aims to purchase shares of TORII Pharmaceutical, a company listed on the Prime Market of the Tokyo Stock Exchange. This development has prompted Shionogi to amend certain information in its Tender Offer Statement, including updates to the conditions of withdrawal, and resubmit it to the Kanto Local Finance Bureau. However, the fundamental terms of the purchase remain unchanged. Shionogi also announces that its Opioid-Induced Constipation product Naldemedine is being reviewed in China, and has contracted with Chia Tai Tianqing Pharmaceutical for import and distribution of Naldemedine to benefit QOL for China’s OIC patients.